Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Cathie Wood's ARK dumps $18M of Twist Bioscience while buying Recursion, Veracyte and Intellia, extending its CRISPR bet to 50 sessions.
Stocks · News reference
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You
A look at the stocks that are owned by Cathie Wood's Ark Invest and Donald Trump.
Why Is Tempus AI Stock Falling Friday?
Tempus AI stock pulled back Friday but stays firmly above key moving averages. Is the TEM rally still intact? Read more.
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
Wedbush Reiterates Outperform on Beam Therapeutics, Maintains $65 Price Target
Wedbush analyst David Nierengarten reiterates Beam Therapeutics (NASDAQ:BEAM) with a Outperform and maintains $65 price target.
Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse
Dutch Bros, SoundHoundAI, Kohl's and Ondas are among the top ten most-heavily shorted stocks in the market right now.